New concentrated insulin approved and available for Canadian patients


ENTUZITY™ KwikPen® is five times more concentrated than the current option


Toronto, ON, December 12, 2017
– Eli Lilly Canada Inc. (Lilly) is pleased to announce the Health Canada approval and availability of ENTUZITY™ KwikPen® (insulin human biosynthetic 500 units/mL) for the treatment of adults and children with diabetes requiring insulin. ENTUZITY is intended for insulin-resistant patients with diabetes requiring daily doses of more than 200 units, as it allows a large dose to be administered subcutaneously in a smaller volumei.

“The management of type 1 and 2 diabetes is an ongoing battle and the addition of new tools is important to ensure the community’s needs are being addressed,” says Dr. Joanne Lorraine, Medical Director, Lilly Diabetes. “Severe insulin resistance is a reality for many Canadians who require higher doses to keep their blood sugar levels on target. ENTUZITY is now available as a convenient option to deliver larger volumes of insulin in an easy-to-use device.”

Before the Canadian approval and availability of ENTUZITY, patients requiring concentrated insulin relied on a vial dose that was administered using a syringe, and access to the vial dose was restricted. Now, physicians have the ability to prescribe an easy-to-use option for their patients who require large doses of insulin.

“Evolving the treatment landscape is a win-win for patients and the medical community,” says Dr. Alice Cheng, Diabetes Specialist and Associate Professor at the University of Toronto. “ENTUZITY will be an important new option for Canadians who struggle with insulin resistance and require more than 200 units per day, because it allows them to simplify their routine with fewer injections.”

-30-

For further information, please contact:

Media contact: Ethan Pigott 
Phone: 416-770-5843
Email: pigott_ethan@network.lilly.com


About Diabetes

Diabetes is a chronic disease that occurs when the body either cannot produce insulin or cannot properly use the insulin it produces. Approximately 3.3 million Canadians have type 1 or type 2 diabetes and this number is expected to rise to 4.8 million by 2024. Diabetes can result in a variety of serious complications, including heart attack, stroke, kidney failure, blindness, problems with erection (impotence) and amputation. Metabolic control has demonstrated reduction in the risk of microvascular complications.

About Eli Lilly Canada Inc.

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people’s needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism. Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world’s first commercially-available insulin. Lilly Canada now employs more than 600 people across the country, working in the areas of oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.

References

i ENTUZITY Canadian Product Monograph 2017.